vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and CSW INDUSTRIALS, INC. (CSW). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $233.0M, roughly 1.2× CSW INDUSTRIALS, INC.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 4.4%, a 91.9% gap on every dollar of revenue. On growth, CSW INDUSTRIALS, INC. posted the faster year-over-year revenue change (20.3% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 5.1%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
ACAD vs CSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $233.0M |
| Net Profit | $273.6M | $10.3M |
| Gross Margin | 90.8% | 39.7% |
| Operating Margin | 6.1% | 7.4% |
| Net Margin | 96.3% | 4.4% |
| Revenue YoY | 9.4% | 20.3% |
| Net Profit YoY | 90.3% | -61.9% |
| EPS (diluted) | $1.61 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $233.0M | ||
| Q3 25 | $278.6M | $277.0M | ||
| Q2 25 | $264.6M | $263.6M | ||
| Q1 25 | $244.3M | $230.5M | ||
| Q4 24 | $259.6M | $193.6M | ||
| Q3 24 | $250.4M | $227.9M | ||
| Q2 24 | $242.0M | $226.2M | ||
| Q1 24 | $205.8M | $210.9M |
| Q4 25 | $273.6M | $10.3M | ||
| Q3 25 | $71.8M | $40.7M | ||
| Q2 25 | $26.7M | $40.9M | ||
| Q1 25 | $19.0M | $35.1M | ||
| Q4 24 | $143.7M | $26.9M | ||
| Q3 24 | $32.8M | $36.1M | ||
| Q2 24 | $33.4M | $38.6M | ||
| Q1 24 | $16.6M | $31.8M |
| Q4 25 | 90.8% | 39.7% | ||
| Q3 25 | 92.2% | 43.0% | ||
| Q2 25 | 92.2% | 43.8% | ||
| Q1 25 | 91.7% | 44.2% | ||
| Q4 24 | 91.6% | 41.4% | ||
| Q3 24 | 92.5% | 45.6% | ||
| Q2 24 | 92.5% | 47.5% | ||
| Q1 24 | 88.8% | 44.4% |
| Q4 25 | 6.1% | 7.4% | ||
| Q3 25 | 12.8% | 20.5% | ||
| Q2 25 | 12.2% | 20.8% | ||
| Q1 25 | 7.9% | 19.5% | ||
| Q4 24 | 59.1% | 15.3% | ||
| Q3 24 | 12.6% | 22.6% | ||
| Q2 24 | 12.6% | 24.3% | ||
| Q1 24 | 7.4% | 21.0% |
| Q4 25 | 96.3% | 4.4% | ||
| Q3 25 | 25.8% | 14.7% | ||
| Q2 25 | 10.1% | 15.5% | ||
| Q1 25 | 7.8% | 15.2% | ||
| Q4 24 | 55.4% | 13.9% | ||
| Q3 24 | 13.1% | 15.8% | ||
| Q2 24 | 13.8% | 17.1% | ||
| Q1 24 | 8.0% | 15.1% |
| Q4 25 | $1.61 | $0.62 | ||
| Q3 25 | $0.42 | $2.41 | ||
| Q2 25 | $0.16 | $2.43 | ||
| Q1 25 | $0.11 | $2.05 | ||
| Q4 24 | $0.86 | $1.60 | ||
| Q3 24 | $0.20 | $2.26 | ||
| Q2 24 | $0.20 | $2.47 | ||
| Q1 24 | $0.10 | $2.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $40.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $1.1B |
| Total Assets | $1.6B | $2.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $40.2M | ||
| Q3 25 | $258.0M | $31.5M | ||
| Q2 25 | $253.6M | $38.0M | ||
| Q1 25 | $217.7M | $225.8M | ||
| Q4 24 | $319.6M | $213.8M | ||
| Q3 24 | $155.1M | $273.2M | ||
| Q2 24 | $177.1M | $18.9M | ||
| Q1 24 | $204.7M | $22.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $800.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $166.0M |
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | $917.3M | $1.1B | ||
| Q2 25 | $822.4M | $1.1B | ||
| Q1 25 | $765.2M | $1.1B | ||
| Q4 24 | $732.8M | $1.0B | ||
| Q3 24 | $577.2M | $1.0B | ||
| Q2 24 | $516.7M | $650.2M | ||
| Q1 24 | $464.0M | $615.7M |
| Q4 25 | $1.6B | $2.3B | ||
| Q3 25 | $1.3B | $1.5B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.2B | $1.4B | ||
| Q3 24 | $976.9M | $1.4B | ||
| Q2 24 | $914.1M | $1.1B | ||
| Q1 24 | $855.1M | $1.0B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $28.9M |
| Free Cash FlowOCF − Capex | — | $22.7M |
| FCF MarginFCF / Revenue | — | 9.8% |
| Capex IntensityCapex / Revenue | — | 2.6% |
| Cash ConversionOCF / Net Profit | -0.18× | 2.81× |
| TTM Free Cash FlowTrailing 4 quarters | — | $162.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $28.9M | ||
| Q3 25 | $74.3M | $61.8M | ||
| Q2 25 | $64.0M | $60.6M | ||
| Q1 25 | $20.3M | $27.3M | ||
| Q4 24 | $40.4M | $11.6M | ||
| Q3 24 | $63.2M | $66.8M | ||
| Q2 24 | $25.0M | $62.7M | ||
| Q1 24 | $29.1M | $22.4M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | $73.9M | $58.7M | ||
| Q2 25 | — | $57.7M | ||
| Q1 25 | — | $22.8M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | $63.2M | $61.3M | ||
| Q2 24 | — | $59.6M | ||
| Q1 24 | — | $17.5M |
| Q4 25 | — | 9.8% | ||
| Q3 25 | 26.5% | 21.2% | ||
| Q2 25 | — | 21.9% | ||
| Q1 25 | — | 9.9% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | 25.2% | 26.9% | ||
| Q2 24 | — | 26.3% | ||
| Q1 24 | — | 8.3% |
| Q4 25 | — | 2.6% | ||
| Q3 25 | 0.1% | 1.1% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | 0.0% | 2.4% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 2.3% |
| Q4 25 | -0.18× | 2.81× | ||
| Q3 25 | 1.03× | 1.52× | ||
| Q2 25 | 2.40× | 1.48× | ||
| Q1 25 | 1.07× | 0.78× | ||
| Q4 24 | 0.28× | 0.43× | ||
| Q3 24 | 1.93× | 1.85× | ||
| Q2 24 | 0.75× | 1.62× | ||
| Q1 24 | 1.76× | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
